Trade Greenwich LifeSciences, Inc. - GLSI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.16 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Greenwich Lifesciences Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 12.04 |
Open* | 11.48 |
1-Year Change* | -16.45% |
Day's Range* | 11.37 - 11.91 |
52 wk Range | 7.58-21.50 |
Average Volume (10 days) | 15.17K |
Average Volume (3 months) | 279.61K |
Market Cap | 136.19M |
P/E Ratio | -100.00K |
Shares Outstanding | 12.85M |
Revenue | N/A |
EPS | -0.70 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Mar 31, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 8, 2023 | 11.64 | 0.16 | 1.39% | 11.48 | 11.91 | 11.37 |
Dec 7, 2023 | 12.04 | 0.25 | 2.12% | 11.79 | 12.23 | 11.78 |
Dec 6, 2023 | 12.13 | 0.51 | 4.39% | 11.62 | 12.37 | 11.44 |
Dec 5, 2023 | 11.79 | 0.50 | 4.43% | 11.29 | 11.97 | 11.23 |
Dec 4, 2023 | 11.39 | 0.23 | 2.06% | 11.16 | 11.42 | 11.16 |
Dec 1, 2023 | 11.66 | 0.23 | 2.01% | 11.43 | 11.75 | 11.25 |
Nov 30, 2023 | 11.36 | 0.27 | 2.43% | 11.09 | 11.68 | 10.87 |
Nov 29, 2023 | 11.19 | 0.21 | 1.91% | 10.98 | 11.74 | 10.98 |
Nov 28, 2023 | 11.35 | 0.17 | 1.52% | 11.18 | 11.57 | 11.09 |
Nov 27, 2023 | 11.48 | -0.50 | -4.17% | 11.98 | 11.98 | 11.20 |
Nov 24, 2023 | 11.74 | 0.64 | 5.77% | 11.10 | 12.02 | 11.10 |
Nov 22, 2023 | 11.13 | 0.57 | 5.40% | 10.56 | 11.63 | 10.56 |
Nov 21, 2023 | 10.57 | -0.36 | -3.29% | 10.93 | 11.08 | 10.54 |
Nov 20, 2023 | 10.84 | 0.27 | 2.55% | 10.57 | 10.94 | 10.53 |
Nov 17, 2023 | 10.59 | -0.19 | -1.76% | 10.78 | 10.87 | 10.33 |
Nov 16, 2023 | 10.53 | -0.26 | -2.41% | 10.79 | 11.18 | 10.53 |
Nov 15, 2023 | 10.78 | 0.62 | 6.10% | 10.16 | 10.90 | 10.13 |
Nov 14, 2023 | 10.30 | 0.17 | 1.68% | 10.13 | 10.40 | 9.91 |
Nov 13, 2023 | 10.03 | -0.02 | -0.20% | 10.05 | 10.11 | 9.76 |
Nov 10, 2023 | 10.06 | 0.28 | 2.86% | 9.78 | 10.17 | 9.78 |
Greenwich LifeSciences, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Friday, December 15, 2023 | ||
Time (UTC) 14:00 | Country US
| Event Greenwich Lifesciences Inc Annual Shareholders Meeting Greenwich Lifesciences Inc Annual Shareholders MeetingForecast -Previous - |
Sunday, March 31, 2024 | ||
Time (UTC) 20:00 | Country US
| Event Q4 2023 Greenwich Lifesciences Inc Earnings Release Q4 2023 Greenwich Lifesciences Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 8.04025 | 4.59794 | 1.86379 | 3.42531 | 1.68966 |
Selling/General/Admin. Expenses, Total | 1.56459 | 1.03843 | 0.80619 | 0.81889 | 0.41964 |
Research & Development | 6.47567 | 3.55952 | 1.05761 | 2.60642 | 1.27002 |
Operating Income | -8.04025 | -4.59794 | -1.86379 | -3.42531 | -1.68966 |
Net Income Before Taxes | -7.82524 | -4.57058 | -1.86296 | -3.42531 | -1.68966 |
Net Income After Taxes | -7.82524 | -4.57058 | -1.86296 | -3.42531 | -1.68966 |
Net Income Before Extra. Items | -7.82524 | -4.57058 | -1.86296 | -3.42531 | -1.68966 |
Net Income | -7.82524 | -4.57058 | -1.86296 | -3.42531 | -1.68966 |
Income Available to Common Excl. Extra. Items | -7.82524 | -4.57058 | -1.86296 | -3.42531 | -1.68966 |
Income Available to Common Incl. Extra. Items | -7.82524 | -4.57058 | -1.86296 | -3.42531 | -1.68966 |
Diluted Net Income | -7.82524 | -4.57058 | -1.86296 | -3.42531 | -1.68966 |
Diluted Weighted Average Shares | 12.9138 | 12.9441 | 12.7035 | 11.9702 | 11.9702 |
Diluted EPS Excluding Extraordinary Items | -0.60596 | -0.3531 | -0.14665 | -0.28615 | -0.14116 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -0.60596 | -0.3531 | -0.14665 | -0.28615 | -0.14116 |
Interest Income (Expense), Net Non-Operating | 0.21502 | 0.02737 | 0.00083 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 2.50293 | 1.74783 | 2.24108 | 2.89468 | 2.38306 |
Selling/General/Admin. Expenses, Total | 0.34476 | 0.36826 | 0.41318 | 0.43658 | 0.65957 |
Research & Development | 2.15817 | 1.37957 | 1.82791 | 2.4581 | 1.72349 |
Operating Income | -2.50293 | -1.74783 | -2.24108 | -2.89468 | -2.38306 |
Interest Income (Expense), Net Non-Operating | 0.11114 | 0.11945 | 0.11618 | 0.10417 | 0.06404 |
Net Income Before Taxes | -2.39179 | -1.62837 | -2.1249 | -2.79051 | -2.31902 |
Net Income After Taxes | -2.39179 | -1.62837 | -2.1249 | -2.79051 | -2.31902 |
Net Income Before Extra. Items | -2.39179 | -1.62837 | -2.1249 | -2.79051 | -2.31902 |
Net Income | -2.39179 | -1.62837 | -2.1249 | -2.79051 | -2.31902 |
Income Available to Common Excl. Extra. Items | -2.39179 | -1.62837 | -2.1249 | -2.79051 | -2.31902 |
Income Available to Common Incl. Extra. Items | -2.39179 | -1.62837 | -2.1249 | -2.79051 | -2.31902 |
Diluted Net Income | -2.39179 | -1.62837 | -2.1249 | -2.79051 | -2.31902 |
Diluted Weighted Average Shares | 12.8482 | 12.8482 | 12.8482 | 12.4525 | 12.8235 |
Diluted EPS Excluding Extraordinary Items | -0.18616 | -0.12674 | -0.16539 | -0.22409 | -0.18084 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.18616 | -0.12674 | -0.16539 | -0.22409 | -0.18084 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 13.468 | 27.2043 | 28.6604 | 0.00684 | 0.0851 |
Cash and Short Term Investments | 13.468 | 27.2043 | 28.6604 | 0.00684 | 0.0851 |
Cash | 13.468 | 27.2043 | 28.6604 | 0.00684 | 0.0851 |
Total Assets | 13.477 | 27.2169 | 28.6766 | 0.02667 | 0.10855 |
Intangibles, Net | 0.009 | 0.01262 | 0.01623 | 0.01984 | 0.02344 |
Total Current Liabilities | 0.26291 | 0.38517 | 1.04549 | 1.37709 | 0.7286 |
Payable/Accrued | 0.22085 | 0.22085 | 0.71097 | 0.73031 | 0.27756 |
Accrued Expenses | 0.04206 | 0.16433 | 0.05937 | 0.01163 | 0.03089 |
Notes Payable/Short Term Debt | 0 | 0 | 0.27515 | 0.63515 | 0 |
Current Port. of LT Debt/Capital Leases | 0.42015 | ||||
Total Liabilities | 0.26291 | 0.38517 | 1.04549 | 1.37709 | 10.2286 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 9.5 |
Long Term Debt | 0 | 9.5 | |||
Total Equity | 13.2141 | 26.8317 | 27.6311 | -1.35042 | -10.1201 |
Preferred Stock - Non Redeemable, Net | 0.00198 | 0.00198 | |||
Common Stock | 0.01285 | 0.01315 | 0.0127 | 0.00846 | 0.0002 |
Additional Paid-In Capital | 54.674 | 60.4661 | 56.6954 | 25.8531 | 13.6664 |
Retained Earnings (Accumulated Deficit) | -41.4728 | -33.6475 | -29.077 | -27.214 | -23.7887 |
Total Liabilities & Shareholders’ Equity | 13.477 | 27.2169 | 28.6766 | 0.02667 | 0.10855 |
Total Common Shares Outstanding | 12.8482 | 13.1478 | 12.7035 | 11.9457 | 11.9457 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 9.14362 | 10.9442 | 11.9112 | 13.468 | 15.6381 |
Cash and Short Term Investments | 9.14362 | 10.9442 | 11.9112 | 13.468 | 15.6381 |
Cash | 9.14362 | 10.9442 | 11.9112 | 13.468 | 15.6381 |
Total Assets | 9.14991 | 10.9514 | 11.9193 | 13.477 | 15.648 |
Intangibles, Net | 0.00629 | 0.0072 | 0.0081 | 0.009 | 0.00991 |
Total Current Liabilities | 0.29729 | 0.30155 | 0.23558 | 0.26291 | 0.23788 |
Payable/Accrued | 0.2309 | 0.30046 | 0.22085 | 0.22085 | 0.22085 |
Accrued Expenses | 0.06639 | 0.00108 | 0.01473 | 0.04206 | 0.01703 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 0.29729 | 0.30155 | 0.23558 | 0.26291 | 0.23788 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 8.85263 | 10.6499 | 11.6837 | 13.2141 | 15.4101 |
Common Stock | 0.01285 | 0.01285 | 0.01285 | 0.01285 | 0.01285 |
Additional Paid-In Capital | 56.4576 | 55.8631 | 55.2686 | 54.674 | 54.0795 |
Retained Earnings (Accumulated Deficit) | -47.6178 | -45.226 | -43.5977 | -41.4728 | -38.6823 |
Total Liabilities & Shareholders’ Equity | 9.14991 | 10.9514 | 11.9193 | 13.477 | 15.648 |
Total Common Shares Outstanding | 12.8482 | 12.8482 | 12.8482 | 12.8482 | 12.8482 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -7.82524 | -4.57058 | -1.86296 | -3.42531 | -1.68966 |
Cash From Operating Activities | -6.20003 | -4.29155 | -1.15296 | -0.29327 | -0.11495 |
Amortization | 0.00361 | 0.00361 | 0.00361 | 0.00361 | 0.00361 |
Changes in Working Capital | -0.12227 | -0.38517 | 0.0284 | 2.93349 | 1.5711 |
Cash From Financing Activities | -7.53622 | 2.83544 | 29.8065 | 0.215 | 0.2 |
Issuance (Retirement) of Stock, Net | -7.53622 | 3.1106 | 30.1665 | 0 | 0.1 |
Issuance (Retirement) of Debt, Net | 0 | -0.27515 | -0.36 | 0.215 | 0.1 |
Net Change in Cash | -13.7362 | -1.45611 | 28.6535 | -0.07827 | 0.08505 |
Non-Cash Items | 1.74387 | 0.66058 | 0.67799 | 0.19494 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -2.1249 | -7.82524 | -5.03473 | -2.7157 | -1.96963 |
Cash From Operating Activities | -1.55681 | -6.20003 | -4.02997 | -2.48016 | -1.94746 |
Amortization | 0.0009 | 0.00361 | 0.00271 | 0.00181 | 0.0009 |
Non-Cash Items | 0.59452 | 1.74387 | 1.14934 | 0.38977 | 0.16527 |
Changes in Working Capital | -0.02733 | -0.12227 | -0.14729 | -0.15604 | -0.144 |
Cash From Financing Activities | 0 | -7.53622 | -7.53622 | -7.53622 | -5.51371 |
Issuance (Retirement) of Stock, Net | 0 | -7.53622 | -7.53622 | -7.53622 | -5.51371 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
Net Change in Cash | -1.55681 | -13.7362 | -11.5662 | -10.0164 | -7.46117 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Patel (Snehal) | Individual Investor | 41.2641 | 5301677 | 6500 | 2023-10-25 | LOW |
McWilliams (David B) | Individual Investor | 4.8281 | 620327 | 0 | 2023-10-24 | LOW |
Hallock (Kenneth) | Individual Investor | 3.0925 | 397333 | 0 | 2023-10-24 | LOW |
Rothe (Eric) | Individual Investor | 2.4381 | 313255 | 0 | 2023-10-24 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1965 | 282215 | -70109 | 2023-06-30 | LOW |
Thompson (Jaye L) | Individual Investor | 2.0224 | 259845 | 600 | 2023-09-26 | LOW |
Daugherty (Frank Joseph) | Individual Investor | 0.7015 | 90133 | 0 | 2023-10-24 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.6164 | 79200 | 28400 | 2023-06-30 | HIGH |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.5308 | 68192 | 2584 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.4387 | 56368 | 620 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3108 | 39933 | 0 | 2023-06-30 | LOW |
Millennium Management LLC | Hedge Fund | 0.2751 | 35348 | -34456 | 2023-06-30 | HIGH |
GSA Capital Partners LLP | Hedge Fund | 0.26 | 33409 | 20751 | 2023-06-30 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1012 | 13002 | 0 | 2023-06-30 | LOW |
HRT Financial LP | Investment Advisor | 0.0789 | 10136 | -8470 | 2023-06-30 | HIGH |
BofA Global Research (US) | Research Firm | 0.0394 | 5060 | -703 | 2023-06-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.0208 | 2671 | 0 | 2023-09-30 | LOW |
Newbridge Capital Management | Investment Advisor/Hedge Fund | 0.0117 | 1500 | 0 | 2023-09-30 | LOW |
Tower Research Capital LLC | Hedge Fund | 0.0096 | 1228 | 127 | 2023-06-30 | HIGH |
Lord, Abbett & Co. LLC | Investment Advisor | 0.0094 | 1207 | 0 | 2023-07-31 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Greenwich LifeSciences, Inc. Company profile
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Industry: | Biopharmaceuticals |
3992 Bluebonnet Dr, Building 14
STAFFORD
TEXAS 77477
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com